Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
The Northwestern Medicine Echocardiography Laboratory supports numerous research initiatives and clinical trials, including investigator-initiated, NIH-funded, and industry-sponsored. Furthermore, we work with multiple companies to support testing and validation of new technologies related to cardiovascular imaging and cardiovascular disease. We have dedicated Core Lab services, statisticians, research sonographers, and administrative support, Additionally, we support clinical and research fellowship in cardiovascular imaging and artificial intelligence.
Below, you will find more information about current areas of research, clinical trials involving echocardiography, recent publications, and echocardiography laboratory faculty areas of research.
Information about clinical trials relating to echocardiography are included in the current areas of research described below. Here you can read about all of the clinical trials related to cardiology.
Recent discoveries within Northwestern Medicine cardiology can be found here.
Structural Heart Disease - Echocardiography is frequently used in interventional cardiology procedures. Read about current therapies below that involve echocardiography to improve structural heart diseases.
Nothwestern Medicine is currently participating in several trials that involve transcatheter heart valve therapies for the tricuspid valve. Read more on the NM Website. The current trials include:
The Edwards PASCAL is device is used in patients with tricuspid regurgitation to treat both functional and degenerative tricuspid disease. The PASCAL clip is an edge-to-edge valve repair with a spacer in the center.
This trial evaluates the safety and effectiveness of the EVOQUE valve replacement with optimal medical therapy (OMT) compared to OMT alone in patients with at least severe tricuspid regurgitation.
The TriClip Tricuspid Valve Repair System is used in patients with severe, symptomatic tricuspid regurgitation and an intermediate or greater risk of mortality for tricuspid valve surgery. Read more about the clinical trial here.
Nothwestern Medicine currently offers several transcatheter heart valve therapies for the mitral valve. Read more on the NM Website. The current commerically available therapies include:
The MitraClip is currently the only FDA approved device for transcatheter mitral valve replacement to repair mitral regurgitation.
This procedure is for patients with a bioprosthetic/tissue valve administered via open heart valve surgery, and the valve is now failing. The TMVR valve is secured inside the failing mitral valve when a balloon on the catheter expands
Current clinical trials include:
This trial is enrolling patients with severe primary MR who are at moderate surgical risk but are suitable candidates for MV surgery. Participants are randomized to receive the MitraClip device or traditional open heart mitral valve repair surgery. Read more about the clinical trial here.
This study is enrolling patients with moderate-to-severe or severe, symptomatic mitral regurgitation who may not respond optimally to transcatheter repair or mitral valve surgery. The study evaluates the effectiveness of the Intrepid Transcatheter Mitral Valve Replacement (TMVR) System.
This study evaluates the Edwards EVOQUE Eos Mitral Valve Replacement System (study device) in patients with moderate to severe mitral regurgitation and high surgical risk.
This study evaluates the Edwards PASCAL Transcatheter Mitral Valve Repair System (PASCAL System) (study device) in patients with functional mitral regurgitation (FMR) on optimal medical therapy. Participants will be randomized to receive either the PASCAL System or the FDA-approved MitraClip System.
Nothwestern Medicine currently offers several transcatheter heart valve therapies for the mitral valve. Read more on the NM Website. The current commerically available therapies include:
The TAVR is available to patients with aortic stenosis. During the procedure, the TAVR valve is advanced by catheter, then expanded via a balloon on the catheter, pushing the diseased valve out of the way.
This is a minimally invasive TAVR procedure for patients who have had previous open heart valve surgery to replace the aortic valve with a bioprosthetic/tissue valve that is now failing. The failing aortic valve is replaced by placing and securing a TAVR valve inside the failing aortic valve.
Current clinical trials include:
This study is enrolling patients who have an existing bioprosthetic aortic valve that is failing and needs to be replaced. Participants receive the SAPIEN 3 transcatheter aortic heart valve (study device) to replace the failing bioprosthetic aortic valve.
Research Interests: cardiac-oncology, cardiac imaging, valvular heart disease, and heart disease in women
Research Interests: cardiology, cardiovascular imaging, valvular heart disease, women in heart disease
Research Interests: aortic aneurysm, cardiovascular diseases, cardiovascular imaging, lipid disorders, preventive medicine, valvular disease, women in heart disease
Website created by Pre-med Intern Avery Longdon.
Copyright © 2022 NM Echo Lab-All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.